Schedule of Investments (unaudited) December 31, 2020 | iShares® Nasdaq Biotechnology ETF (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Common Stocks | ||||||||
Biotechnology — 79.7% | ||||||||
AC Immune SA(a)(b) | 618,204 | $ | 3,196,115 | |||||
ACADIA Pharmaceuticals Inc.(a)(b) | 1,378,909 | 73,716,475 | ||||||
Acceleron Pharma Inc.(a)(b) | 522,598 | 66,861,188 | ||||||
Achillion Pharmaceuticals Inc.(b)(c) | 4,112 | 1,892 | ||||||
Adaptimmune Therapeutics PLC, ADR(a)(b) | 1,177,436 | 6,346,380 | ||||||
Adicet Bio Inc.(a) | 176,358 | 2,477,830 | ||||||
Adverum Biotechnologies Inc.(a)(b) | 848,736 | 9,200,298 | ||||||
Aeglea BioTherapeutics Inc.(a) | 413,216 | 3,252,010 | ||||||
Affimed NV(a) | 761,277 | 4,430,632 | ||||||
Agios Pharmaceuticals Inc.(a)(b) | 600,707 | 26,028,634 | ||||||
Akebia Therapeutics Inc.(a)(b) | 1,245,587 | 3,487,644 | ||||||
Akero Therapeutics Inc.(a)(b) | 303,407 | 7,827,901 | ||||||
Akouos Inc.(a)(b) | 297,567 | 5,900,754 | ||||||
Alector Inc.(a)(b) | 689,656 | 10,434,495 | ||||||
Alexion Pharmaceuticals Inc.(a) | 1,898,150 | 296,566,956 | ||||||
Alkermes PLC(a)(b) | 1,380,449 | 27,539,958 | ||||||
Allakos Inc.(a)(b) | 455,411 | 63,757,540 | ||||||
Allogene Therapeutics Inc.(a)(b) | 1,216,756 | 30,710,921 | ||||||
Allovir Inc.(a)(b) | 566,460 | 21,774,722 | ||||||
Alnylam Pharmaceuticals Inc.(a)(b) | 1,007,684 | 130,968,689 | ||||||
Altimmune Inc.(a)(b) | 286,218 | 3,228,539 | ||||||
ALX Oncology Holdings Inc.(a)(b) | 321,843 | 27,742,867 | ||||||
Amarin Corp. PLC, ADR(a)(b) | 3,337,808 | 16,321,881 | ||||||
Amgen Inc. | 3,568,494 | 820,468,140 | ||||||
Amicus Therapeutics Inc.(a)(b) | 2,260,235 | 52,188,826 | ||||||
AnaptysBio Inc.(a)(b) | 235,659 | 5,066,669 | ||||||
Annexon Inc.(a) | 330,243 | 8,265,982 | ||||||
Apellis Pharmaceuticals Inc.(a)(b) | 656,920 | 37,575,824 | ||||||
Applied Molecular Transport Inc.(a)(b) | 301,880 | 9,288,848 | ||||||
Applied Therapeutics Inc.(a) | 194,625 | 4,283,696 | ||||||
Aprea Therapeutics Inc.(a)(b) | 183,366 | 902,161 | ||||||
Arbutus Biopharma Corp.(a)(b) | 734,858 | 2,608,746 | ||||||
Arcturus Therapeutics Holdings Inc.(a) | 213,056 | 9,242,369 | ||||||
Arcutis Biotherapeutics Inc.(a) | 377,643 | 10,623,098 | ||||||
Ardelyx Inc.(a)(b) | 777,728 | 5,031,900 | ||||||
Arena Pharmaceuticals Inc.(a)(b) | 504,502 | 38,760,889 | ||||||
Argenx SE, ADR(a)(b) | 215,586 | 63,401,687 | ||||||
Arrowhead Pharmaceuticals Inc.(a)(b) | 891,261 | 68,386,457 | ||||||
Ascendis Pharma A/S, ADR(a)(b) | 449,256 | 74,926,916 | ||||||
Assembly Biosciences Inc.(a) | 284,583 | 1,721,727 | ||||||
Atara Biotherapeutics Inc.(a) | 674,761 | 13,245,558 | ||||||
Athenex Inc.(a)(b) | 813,677 | 8,999,268 | ||||||
Atreca Inc., Class A(a)(b) | 258,466 | 4,174,226 | ||||||
Aurinia Pharmaceuticals Inc.(a)(b) | 1,098,915 | 15,197,994 | ||||||
Autolus Therapeutics PLC , ADR(a)(b) | 291,494 | 2,605,956 | ||||||
Avidity Biosciences Inc.(a) | 324,782 | 8,288,437 | ||||||
Avrobio Inc.(a)(b) | 357,359 | 4,981,584 | ||||||
Beam Therapeutics Inc.(a) | 502,727 | 41,042,632 | ||||||
BeiGene Ltd., ADR(a)(b) | 410,252 | 106,005,014 | ||||||
BioCryst Pharmaceuticals Inc.(a)(b) | 1,533,960 | 11,428,002 | ||||||
Biogen Inc.(a) | 1,334,650 | 326,802,399 | ||||||
BioMarin Pharmaceutical Inc.(a)(b) | 1,574,501 | 138,067,993 | ||||||
BioNTech SE, ADR(a)(b) | 575,828 | 46,941,499 | ||||||
Black Diamond Therapeutics Inc.(a)(b) | 311,531 | 9,984,569 | ||||||
Bluebird Bio Inc.(a)(b) | 575,666 | 24,909,068 | ||||||
Blueprint Medicines Corp.(a)(b) | 483,388 | 54,211,964 | ||||||
Bridgebio Pharma Inc.(a)(b) | 1,063,107 | 75,597,539 | ||||||
Cabaletta Bio Inc.(a)(b) | 208,190 | 2,598,211 |
Security | Shares | Value | ||||||
Biotechnology (continued) | ||||||||
Calithera Biosciences Inc.(a)(b) | 610,659 | $ | 2,998,336 | |||||
Cellectis SA, ADR(a)(b) | 154,219 | 4,173,166 | ||||||
ChemoCentryx Inc.(a)(b) | 600,277 | 37,169,152 | ||||||
China Biologic Products Holdings Inc.(a)(b) | 336,438 | 39,736,692 | ||||||
Chinook Therapeutics Inc.(a) | 364,865 | 5,786,759 | ||||||
Clovis Oncology Inc.(a)(b) | 764,368 | 3,668,966 | ||||||
Coherus Biosciences Inc.(a)(b) | 627,020 | 10,897,608 | ||||||
Concert Pharmaceuticals Inc.(a) | 265,256 | 3,352,836 | ||||||
Constellation Pharmaceuticals Inc.(a) | 411,749 | 11,858,371 | ||||||
Cortexyme Inc.(a)(b) | 255,294 | 7,092,067 | ||||||
Crinetics Pharmaceuticals Inc.(a) | 284,931 | 4,020,376 | ||||||
CRISPR Therapeutics AG(a)(b) | 612,812 | 93,827,645 | ||||||
Cytokinetics Inc.(a)(b) | 614,967 | 12,779,014 | ||||||
CytomX Therapeutics Inc.(a)(b) | 398,348 | 2,609,179 | ||||||
Deciphera Pharmaceuticals Inc.(a)(b) | 493,835 | 28,183,163 | ||||||
Denali Therapeutics Inc.(a)(b) | 1,040,098 | 87,118,608 | ||||||
Dicerna Pharmaceuticals Inc.(a) | 651,526 | 14,353,118 | ||||||
Eagle Pharmaceuticals Inc./DE(a)(b) | 112,263 | 5,228,088 | ||||||
Editas Medicine Inc.(a)(b) | 540,671 | 37,906,444 | ||||||
Eidos Therapeutics Inc.(a)(b) | 335,363 | 44,127,064 | ||||||
Eiger BioPharmaceuticals Inc.(a) | 280,332 | 3,445,280 | ||||||
Enanta Pharmaceuticals Inc.(a)(b) | 175,451 | 7,386,487 | ||||||
Epizyme Inc.(a)(b) | 883,981 | 9,600,034 | ||||||
Esperion Therapeutics Inc.(a)(b) | 244,025 | 6,344,650 | ||||||
Exelixis Inc.(a) | 2,690,914 | 54,006,644 | ||||||
Fate Therapeutics Inc.(a)(b) | 756,706 | 68,807,277 | ||||||
FibroGen Inc.(a)(b) | 789,409 | 29,279,180 | ||||||
Five Prime Therapeutics Inc.(a) | 402,473 | 6,846,066 | ||||||
Flexion Therapeutics Inc.(a)(b) | 424,963 | 4,904,073 | ||||||
Forma Therapeutics Holdings Inc.(a)(b) | 356,255 | 12,433,300 | ||||||
Frequency Therapeutics Inc.(a)(b) | 291,960 | 10,294,510 | ||||||
Fusion Pharmaceuticals Inc.(a) | 361,119 | 4,243,148 | ||||||
G1 Therapeutics Inc.(a) | 333,354 | 5,997,038 | ||||||
Galapagos NV, ADR(a)(b) | 58,126 | 5,753,311 | ||||||
Gamida Cell Ltd.(a)(b) | 428,160 | 3,592,262 | ||||||
Generation Bio Co.(a)(b) | 402,583 | 11,413,228 | ||||||
Genmab A/S, ADR(a)(b) | 396,999 | 16,141,979 | ||||||
Geron Corp.(a)(b) | 2,675,378 | 4,253,851 | ||||||
Gilead Sciences Inc. | 10,854,070 | 632,358,118 | ||||||
Global Blood Therapeutics Inc.(a)(b) | 535,988 | 23,213,640 | ||||||
Gossamer Bio Inc.(a)(b) | 663,700 | 6,417,979 | ||||||
Grifols SA, ADR | 1,033,145 | 19,051,194 | ||||||
Halozyme Therapeutics Inc.(a)(b) | 1,172,521 | 50,078,372 | ||||||
Harpoon Therapeutics Inc.(a)(b) | 219,660 | 3,648,553 | ||||||
Homology Medicines Inc.(a)(b) | 390,041 | 4,403,563 | ||||||
Ideaya Biosciences Inc.(a) | 251,586 | 3,522,204 | ||||||
IGM Biosciences Inc.(a)(b) | 210,046 | 18,544,961 | ||||||
I-Mab, SP ADR, SP ADR(a) | 136,149 | 6,419,425 | ||||||
Immunic Inc.(a) | 179,311 | 2,741,665 | ||||||
ImmunoGen Inc.(a) | 1,630,408 | 10,516,132 | ||||||
Immunovant Inc.(a) | 848,991 | 39,214,894 | ||||||
Incyte Corp.(a) | 1,899,455 | 165,214,596 | ||||||
Inovio Pharmaceuticals Inc.(a)(b) | 1,470,221 | 13,011,456 | ||||||
Inozyme Pharma Inc.(a)(b) | 202,285 | 4,175,162 | ||||||
Insmed Inc.(a)(b) | 883,580 | 29,414,378 | ||||||
Intellia Therapeutics Inc.(a)(b) | 512,448 | 27,877,171 | ||||||
Intercept Pharmaceuticals Inc.(a)(b) | 288,098 | 7,116,021 | ||||||
Ionis Pharmaceuticals Inc.(a)(b) | 1,212,765 | 68,569,733 | ||||||
Iovance Biotherapeutics Inc.(a)(b) | 1,272,296 | 59,034,534 | ||||||
Ironwood Pharmaceuticals Inc.(a)(b) | 1,388,548 | 15,815,562 |
1 |
Schedule of Investments (unaudited) (continued) December 31, 2020 | iShares® Nasdaq Biotechnology ETF (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Biotechnology (continued) | ||||||||
iTeos Therapeutics Inc.(a) | 303,302 | $ | 10,257,674 | |||||
IVERIC bio Inc.(a)(b) | 775,174 | 5,356,452 | ||||||
Jounce Therapeutics Inc.(a) | 344,898 | 2,414,286 | ||||||
Kadmon Holdings Inc.(a)(b) | 1,484,387 | 6,160,206 | ||||||
KalVista Pharmaceuticals Inc.(a) | 154,985 | 2,943,165 | ||||||
Kamada Ltd., NVS(a)(b) | 387,131 | 2,508,609 | ||||||
Karuna Therapeutics Inc.(a)(b) | 232,505 | 23,620,183 | ||||||
Karyopharm Therapeutics Inc.(a)(b) | 640,736 | 9,918,593 | ||||||
Keros Therapeutics Inc.(a) | 200,603 | 14,150,536 | ||||||
Kezar Life Sciences Inc.(a)(b) | 400,438 | 2,090,286 | ||||||
Kiniksa Pharmaceuticals Ltd., Class A(a)(b) | 273,812 | 4,838,258 | ||||||
Kodiak Sciences Inc.(a)(b) | 440,040 | 64,646,276 | ||||||
Krystal Biotech Inc.(a) | 170,560 | 10,233,600 | ||||||
Kura Oncology Inc.(a)(b) | 491,845 | 16,063,658 | ||||||
Larimar Therapeutics Inc.(a) | 132,900 | 2,845,389 | ||||||
Legend Biotech Corp., ADR, ADR(a)(b) | 184,738 | 5,202,222 | ||||||
Ligand Pharmaceuticals Inc.(a)(b) | 139,501 | 13,873,374 | ||||||
MacroGenics Inc.(a) | 488,640 | 11,170,310 | ||||||
Madrigal Pharmaceuticals Inc.(a) | 133,856 | 14,880,772 | ||||||
Magenta Therapeutics Inc.(a)(b) | 416,243 | 3,263,345 | ||||||
MannKind Corp.(a)(b) | 2,031,539 | 6,358,717 | ||||||
MediciNova Inc.(a) | 388,832 | 2,045,256 | ||||||
MeiraGTx Holdings PLC(a) | 376,675 | 5,702,860 | ||||||
Mersana Therapeutics Inc.(a) | 592,820 | 15,774,940 | ||||||
Mirati Therapeutics Inc.(a) | 436,097 | 95,784,345 | ||||||
Moderna Inc.(a)(b) | 3,426,394 | 357,955,381 | ||||||
Myriad Genetics Inc.(a)(b) | 654,075 | 12,934,333 | ||||||
NantKwest Inc.(a)(b) | 939,830 | 12,527,934 | ||||||
Neoleukin Therapeutics Inc.(a) | 362,584 | 5,112,434 | ||||||
Neurocrine Biosciences Inc.(a)(b) | 810,345 | 77,671,568 | ||||||
NextCure Inc.(a) | 238,465 | 2,599,269 | ||||||
Nkarta Inc.(a)(b) | 282,102 | 17,340,810 | ||||||
Novavax Inc.(a)(b) | 552,117 | 61,566,567 | ||||||
Nurix Therapeutics Inc.(a)(b) | 336,280 | 11,056,886 | ||||||
OPKO Health Inc.(a)(b) | 5,811,546 | 22,955,607 | ||||||
Orchard Therapeutics PLC(a)(b) | 523,457 | 2,261,334 | ||||||
ORIC Pharmaceuticals Inc.(a)(b) | 317,069 | 10,732,786 | ||||||
Ovid therapeutics Inc.(a) | 549,012 | 1,268,218 | ||||||
Pandion Therapeutics Inc.(a)(b) | 255,483 | 3,793,923 | ||||||
Passage Bio Inc.(a)(b) | 394,087 | 10,076,805 | ||||||
Poseida Therapeutics Inc.(a) | 535,029 | 5,869,268 | ||||||
Precigen Inc.(a) | 1,609,813 | 16,420,093 | ||||||
Precision BioSciences Inc.(a)(b) | 452,246 | 3,771,732 | ||||||
Prevail Therapeutics Inc.(a) | 299,781 | 6,915,948 | ||||||
Protagonist Therapeutics Inc.(a) | 334,787 | 6,749,306 | ||||||
Prothena Corp. PLC(a) | 344,000 | 4,131,440 | ||||||
PTC Therapeutics Inc.(a)(b) | 591,875 | 36,122,131 | ||||||
Puma Biotechnology Inc.(a)(b) | 342,634 | 3,515,425 | ||||||
Radius Health Inc.(a)(b) | 406,635 | 7,262,501 | ||||||
Rapt Therapeutics Inc.(a) | 212,515 | 4,197,171 | ||||||
Regeneron Pharmaceuticals Inc.(a)(b) | 907,952 | 438,640,691 | ||||||
REGENXBIO Inc.(a)(b) | 324,739 | 14,730,161 | ||||||
Relay Therapeutics Inc.(a)(b) | 780,440 | 32,435,086 | ||||||
Repare Therapeutics Inc.(a)(b) | 318,190 | 10,913,917 | ||||||
Replimune Group Inc.(a)(b) | 397,791 | 15,175,727 | ||||||
REVOLUTION Medicines Inc.(a)(b) | 577,133 | 22,848,695 | ||||||
Rhythm Pharmaceuticals Inc.(a)(b) | 384,671 | 11,436,269 | ||||||
Rigel Pharmaceuticals Inc.(a)(b) | 1,456,109 | 5,096,382 | ||||||
Rocket Pharmaceuticals Inc.(a)(b) | 479,099 | 26,273,789 | ||||||
Rubius Therapeutics Inc.(a)(b) | 697,353 | 5,292,909 |
Security | Shares | Value | ||||||
Biotechnology (continued) | ||||||||
Sage Therapeutics Inc.(a) | 451,436 | $ | 39,053,728 | |||||
Sangamo Therapeutics Inc.(a)(b) | 1,226,742 | 19,143,309 | ||||||
Sarepta Therapeutics Inc.(a)(b) | 684,451 | 116,692,051 | ||||||
Scholar Rock Holding Corp.(a) | 292,133 | 14,177,215 | ||||||
Seagen Inc.(a) | 1,563,869 | 273,896,017 | ||||||
Selecta Biosciences Inc.(a) | 934,967 | 2,832,950 | ||||||
Seres Therapeutics Inc.(a)(b) | 791,402 | 19,389,349 | ||||||
Spectrum Pharmaceuticals Inc.(a)(b) | 1,257,449 | 4,287,901 | ||||||
Spero Therapeutics Inc.(a)(b) | 235,296 | 4,562,389 | ||||||
SpringWorks Therapeutics Inc.(a)(b) | 422,951 | 30,672,407 | ||||||
Stoke Therapeutics Inc.(a)(b) | 314,290 | 19,463,980 | ||||||
Summit Therapeutics Inc.(a) | 711,929 | 3,346,066 | ||||||
Surface Oncology Inc.(a)(b) | 352,045 | 3,252,896 | ||||||
Sutro Biopharma Inc.(a) | 334,103 | 7,253,376 | ||||||
Syndax Pharmaceuticals Inc.(a) | 353,709 | 7,866,488 | ||||||
Syros Pharmaceuticals Inc.(a)(b) | 394,781 | 4,283,374 | ||||||
TCR2 Therapeutics Inc.(a) | 289,255 | 8,946,657 | ||||||
Translate Bio Inc.(a)(b) | 644,744 | 11,882,632 | ||||||
Travere Therapeutics, Inc.(a) | 443,826 | 12,096,478 | ||||||
Turning Point Therapeutics Inc.(a)(b) | 417,831 | 50,912,707 | ||||||
Twist Bioscience Corp.(a)(b) | 391,625 | 55,332,696 | ||||||
Ultragenyx Pharmaceutical Inc.(a)(b) | 571,815 | 79,156,350 | ||||||
uniQure NV(a) | 385,923 | 13,943,398 | ||||||
United Therapeutics Corp.(a) | 385,455 | 58,508,214 | ||||||
UNITY Biotechnology Inc.(a)(b) | 455,973 | 2,389,299 | ||||||
UroGen Pharma Ltd.(a)(b) | 190,389 | 3,430,810 | ||||||
Vanda Pharmaceuticals Inc.(a)(b) | 479,056 | 6,294,796 | ||||||
Vaxcyte Inc.(a) | 440,954 | 11,716,148 | ||||||
Veracyte Inc.(a)(b) | 502,142 | 24,574,829 | ||||||
Verastem Inc.(a)(b) | 1,469,336 | 3,129,686 | ||||||
Vertex Pharmaceuticals Inc.(a) | 2,251,637 | 532,151,889 | ||||||
Viela Bio Inc.(a)(b) | 474,602 | 17,071,434 | ||||||
Vir Biotechnology Inc.(a)(b) | 1,104,848 | 29,587,829 | ||||||
Voyager Therapeutics Inc.(a)(b) | 322,831 | 2,308,242 | ||||||
XBiotech Inc.(a)(b) | 252,162 | 3,946,335 | ||||||
Xencor Inc.(a)(b) | 498,315 | 21,741,483 | ||||||
Xenon Pharmaceuticals Inc.(a)(b) | 302,974 | 4,659,740 | ||||||
Y-mAbs Therapeutics Inc.(a)(b) | 351,376 | 17,396,626 | ||||||
Zai Lab Ltd., ADR(a)(b) | 483,158 | 65,390,604 | ||||||
Zentalis Pharmaceuticals Inc.(a)(b) | 353,586 | 18,365,257 | ||||||
ZIOPHARM Oncology Inc.(a)(b) | 1,854,615 | 4,673,630 | ||||||
|
| |||||||
8,151,125,525 | ||||||||
Health Care Equipment & Supplies — 0.0% | ||||||||
LENSAR Inc.(a) | 1 | 7 | ||||||
|
| |||||||
Health Care Providers & Services — 1.3% | ||||||||
Castle Biosciences Inc.(a) | 173,314 | 11,638,035 | ||||||
Guardant Health Inc.(a)(b) | 867,120 | 111,754,426 | ||||||
PetIQ Inc.(a)(b) | 221,143 | 8,502,948 | ||||||
|
| |||||||
131,895,409 | ||||||||
Life Sciences Tools & Services — 7.9% | ||||||||
Adaptive Biotechnologies Corp.(a)(b) | 1,186,283 | 70,144,914 | ||||||
Codexis Inc.(a)(b) | 513,063 | 11,200,165 | ||||||
Compugen Ltd.(a)(b) | 722,449 | 8,748,857 | ||||||
Illumina Inc.(a)(b) | 1,230,045 | 455,116,650 | ||||||
Luminex Corp. | 405,326 | 9,371,137 | ||||||
Medpace Holdings Inc.(a)(b) | 310,263 | 43,188,610 | ||||||
NanoString Technologies Inc.(a) | 382,198 | 25,561,402 | ||||||
Pacific Biosciences of California Inc.(a)(b) | 1,623,916 | 42,124,381 | ||||||
Personalis Inc.(a)(b) | 338,281 | 12,384,468 |
2 |
Schedule of Investments (unaudited) (continued) December 31, 2020 | iShares® Nasdaq Biotechnology ETF (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Life Sciences Tools & Services (continued) | ||||||||
PRA Health Sciences Inc.(a)(b) | 556,399 | $ | 69,794,691 | |||||
Syneos Health Inc.(a)(b) | 902,016 | 61,454,350 | ||||||
|
| |||||||
809,089,625 | ||||||||
Pharmaceuticals — 10.9% | ||||||||
Aerie Pharmaceuticals Inc.(a)(b) | 403,429 | 5,450,326 | ||||||
Amphastar Pharmaceuticals Inc.(a)(b) | 414,999 | 8,345,630 | ||||||
ANI Pharmaceuticals Inc.(a) | 106,408 | 3,090,088 | ||||||
Arvinas Inc.(a)(b) | 351,708 | 29,870,560 | ||||||
AstraZeneca PLC | 4,242,078 | 212,061,479 | ||||||
Avadel Pharmaceuticals PLC, ADR(a)(b) | 569,229 | 3,802,450 | ||||||
Axsome Therapeutics Inc.(a)(b) | 323,904 | 26,388,459 | ||||||
BioDelivery Sciences International Inc.(a)(b) | 871,404 | 3,659,897 | ||||||
Cara Therapeutics Inc.(a)(b) | 436,635 | 6,606,288 | ||||||
Chiasma Inc.(a)(b) | 498,110 | 2,166,779 | ||||||
Collegium Pharmaceutical Inc.(a)(b) | 303,618 | 6,081,469 | ||||||
Cymabay Therapeutics Inc.(a)(b) | 593,609 | 3,407,316 | ||||||
Endo International PLC(a)(b) | 2,003,713 | 14,386,659 | ||||||
Fulcrum Therapeutics Inc.(a) | 237,679 | 2,783,221 | ||||||
GW Pharmaceuticals PLC, ADR(a)(b) | 260,679 | 30,084,963 | ||||||
Horizon Therapeutics PLC(a) | 1,914,320 | 140,032,508 | ||||||
Hutchison China MediTech Ltd., ADR(a)(b) | 447,620 | 14,332,792 | ||||||
Innoviva Inc.(a)(b) | 882,282 | 10,931,474 | ||||||
Intra-Cellular Therapies Inc.(a)(b) | 695,213 | 22,107,773 | ||||||
Jazz Pharmaceuticals PLC(a) | 483,237 | 79,758,267 | ||||||
Kala Pharmaceuticals Inc.(a)(b) | 485,308 | 3,290,388 | ||||||
Kaleido Biosciences Inc.(a)(b) | 311,414 | 2,833,867 | ||||||
Marinus Pharmaceuticals Inc.(a) | 264,780 | 3,230,316 | ||||||
Nektar Therapeutics(a)(b) | 1,556,080 | 26,453,360 | ||||||
NGM Biopharmaceuticals Inc.(a)(b) | 598,611 | 18,134,920 | ||||||
Ocular Therapeutix Inc.(a)(b) | 617,869 | 12,789,888 | ||||||
Odonate Therapeutics Inc.(a) | 333,425 | 6,401,760 | ||||||
Omeros Corp.(a)(b) | 538,389 | 7,690,887 | ||||||
Osmotica Pharmaceuticals PLC(a)(b) | 539,275 | 2,221,813 | ||||||
Pacira BioSciences Inc.(a)(b) | 376,807 | 22,548,131 | ||||||
Paratek Pharmaceuticals Inc.(a)(b) | 395,011 | 2,472,769 | ||||||
Phibro Animal Health Corp., Class A | 175,581 | 3,409,783 | ||||||
Pliant Therapeutics Inc.(a) | 307,063 | 6,976,471 | ||||||
Provention Bio Inc.(a)(b) | 488,882 | 8,281,661 | ||||||
Reata Pharmaceuticals Inc., Class A(a)(b) | 250,140 | 30,922,307 | ||||||
Redhill Biopharma Ltd., SP ADR, SP ADR NVS(a)(b) | 324,096 | 2,618,696 | ||||||
Relmada Therapeutics Inc.(a) | 140,564 | 4,507,888 | ||||||
Restorbio Inc.(b) | 50,902 | 105,469 | ||||||
Revance Therapeutics Inc.(a)(b) | 577,510 | 16,366,633 | ||||||
Royalty Pharma PLC, Class A | 3,366,138 | 168,475,207 | ||||||
Sanofi, ADR | 1,770,955 | 86,050,703 | ||||||
SIGA Technologies Inc.(a)(b) | 666,932 | 4,848,596 | ||||||
Supernus Pharmaceuticals Inc.(a)(b) | 458,888 | 11,545,622 | ||||||
TherapeuticsMD Inc.(a)(b) | 2,584,293 | 3,126,995 |
Security | Shares | Value | ||||||
Pharmaceuticals (continued) | ||||||||
Theravance Biopharma Inc.(a)(b) | 556,860 | $ | 9,895,402 | |||||
Tricida Inc.(a) | 432,469 | 3,048,906 | ||||||
VYNE Therapeutics Inc.(a)(b) | 1,452,929 | 2,295,628 | ||||||
WaVe Life Sciences Ltd.(a) | 420,495 | 3,309,296 | ||||||
Xeris Pharmaceuticals Inc.(a)(b) | 422,138 | 2,076,919 | ||||||
Zogenix Inc.(a)(b) | 485,109 | 9,697,329 | ||||||
|
| |||||||
1,110,976,008 | ||||||||
|
| |||||||
Total Common Stocks — 99.8% | 10,203,086,574 | |||||||
|
| |||||||
Short-Term Investments | ||||||||
Money Market Funds — 11.5% | ||||||||
BlackRock Cash Funds: Institutional, SL Agency Shares, 0.18%(d)(e)(f) | 1,158,389,297 | 1,159,084,330 | ||||||
BlackRock Cash Funds: Treasury, SL Agency Shares, 0.00%(d)(e) | 17,580,000 | 17,580,000 | ||||||
|
| |||||||
1,176,664,330 | ||||||||
|
| |||||||
Total Short-Term Investments — 11.5% |
| 1,176,664,330 | ||||||
|
| |||||||
Total Investments Before Investments Sold |
| 11,379,750,904 | ||||||
Investments Sold Short — (0.0%) |
| |||||||
Common Stocks — (0.0%)% |
| |||||||
PDL BioPharma Inc.(a) | (4,374 | ) | (10,804 | ) | ||||
|
| |||||||
Total Investments Sold Short | (10,804 | ) | ||||||
|
| |||||||
Total Investments, Net of Investments |
| 11,379,740,100 | ||||||
Other Assets, Less Liabilities — (11.3)% |
| (1,158,724,378 | ) | |||||
|
| |||||||
Net Assets — 100.0% | $ | 10,221,015,722 | ||||||
|
|
(a) | Non-income producing security. |
(b) | All or a portion of this security is on loan. |
(c) | Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. |
(d) | Affiliate of the Fund. |
(e) | Annualized 7-day yield as of period-end. |
(f) | All or a portion of this security was purchased with cash collateral received from loaned securities. |
3 |
Schedule of Investments (unaudited) (continued) December 31, 2020 | iShares® Nasdaq Biotechnology ETF |
Affiliates
Investments in issuers considered to be affiliate(s) of the Fund during the period ended December 31, 2020 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
Affiliated Issuer | Value at 03/31/20 | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation (Depreciation) | Value at 12/31/20 | Shares Held at 12/31/20 | Income | Capital Gain Distributions from Underlying Funds |
| ||||||||||||||||||||||||||||||
BlackRock Cash Funds: Institutional, SL Agency Shares | $ | 930,848,306 | $ | 227,678,392 | (a) | $ | — | $ | (190,900 | ) | $ | 748,532 | $ | 1,159,084,330 | 1,158,389,297 | $ | 7,951,494 | (b) | $ | — | ||||||||||||||||||||
BlackRock Cash Funds: Treasury, SL Agency Shares | 12,684,000 | 4,896,000 | (a) | — | — | — | 17,580,000 | 17,580,000 | 10,561 | — | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||||||
$ | (190,900 | ) | $ | 748,532 | $ | 1,176,664,330 | $ | 7,962,055 | $ | — | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
(a) | Represents net amount purchased (sold). |
(b) | All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Futures Contracts
| ||||||||||||||||
Description | Number of Contracts | Expiration Date | Notional Amount (000) | Value/ Unrealized Appreciation (Depreciation) | ||||||||||||
| ||||||||||||||||
Long Contracts | ||||||||||||||||
Russell 2000 E-Mini Index | 52 | 03/19/21 | $ 5,135 | $ | 34,812 | |||||||||||
S&P Select Sector Health Care E-Mini Index | 107 | 03/19/21 | 12,263 | 111,189 | ||||||||||||
|
| |||||||||||||||
$ | 146,001 | |||||||||||||||
|
|
Fair Value Measurements
Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.
The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of December 31, 2020. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.
| ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| ||||||||||||||||
Investments | ||||||||||||||||
Assets | ||||||||||||||||
Common Stocks | $ | 10,202,979,213 | $ | 105,469 | $ | 1,892 | $ | 10,203,086,574 | ||||||||
Money Market Funds | 1,176,664,330 | — | — | 1,176,664,330 | ||||||||||||
Liabilities | ||||||||||||||||
Common Stocks | — | (10,804 | ) | — | (10,804 | ) | ||||||||||
|
|
|
|
|
|
|
| |||||||||
$ | 11,379,643,543 | $ | 94,665 | $ | 1,892 | $ | 11,379,740,100 | |||||||||
|
|
|
|
|
|
|
| |||||||||
Derivative financial instruments(a) | ||||||||||||||||
Assets | ||||||||||||||||
Futures Contracts | $ | 146,001 | $ | — | $ | — | $ | 146,001 | ||||||||
|
|
|
|
|
|
|
|
(a) | Shown at the unrealized appreciation (depreciation) on the contracts. |
Portfolio Abbreviations - Equity | ||
ADR | American Depositary Receipt | |
NVS | Non-Voting Shares |
4 |